Cargando…

Dosimetry-Based Consideration on Remission and Relapse after Therapy with (223)Ra-Dichloride in Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases. A Case Report

Here, we present the case of a 64-year-old male patient diagnosed with castration-resistant prostate cancer (CRPC) with bone metastasis, treated with abiraterone prednisone/prednisolone in combination with (223)Ra-dichloride therapy, who had remission and a subsequent relapse of bone metastasis on r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mangano, Anna Maria, Pacilio, Massimiliano, Ialongo, Pasquale, Semprebene, Alessandro, Ventroni, Guido, Mango, Lucio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872001/ https://www.ncbi.nlm.nih.gov/pubmed/29495541 http://dx.doi.org/10.3390/diagnostics8010018

Ejemplares similares

The role of dosimetry and biological effects in metastatic castration–resistant prostate cancer (mCRPC) patients treated with (223)Ra: first in human study
por: Sciuto, Rosa, et al.
Publicado: (2021)

Response to (223)Ra-dichloride in castration-resistant prostate cancer with bone metastasis: A case report
por: Cabrera, Montserrat Estorch, et al.
Publicado: (2016)

(223)Ra-Dichloride in castration-resistant metastatic prostate cancer: improving outcomes and identifying predictors of survival in clinical practice
por: Dizdarevic, Sabina, et al.
Publicado: (2018)

Evaluation of Alpha-Therapy with Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—the Role of Gamma Scintigraphy in Dosimetry and Pharmacokinetics
por: Kairemo, Kalevi, et al.
Publicado: (2015)

(223)Ra-dichloride therapy of bone metastasis: optimization of SPECT images for quantification
por: Benabdallah, Nadia, et al.
Publicado: (2019)

Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride
por: Lien, Lise Marie E, et al.
Publicado: (2015)

Validation of the 3-variable prognostic score (3-PS) in mCRPC patients treated with (223)Radium-dichloride: a national multicenter study
por: Frantellizzi, Viviana, et al.
Publicado: (2020)

Ultrastructural Analysis of Cancer Cells Treated with the Radiopharmaceutical Radium Dichloride ([(223)Ra]RaCl(2)): Understanding the Effect on Cell Structure
por: Diniz Filho, Joel Félix Silva, et al.
Publicado: (2023)

Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2017)

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
por: Uemura, Hiroji, et al.
Publicado: (2017)

A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide
por: Petrylak, D.P., et al.
Publicado: (2021)

Radium 223 dichloride for prostate cancer treatment
por: Deshayes, Emmanuel, et al.
Publicado: (2017)

Radium-223 dichloride: illustrating the benefits of a multidisciplinary approach for patients with metastatic castration-resistant prostate cancer
por: Renzulli, Joseph F, et al.
Publicado: (2015)

A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
por: Fong, Lawrence, et al.
Publicado: (2021)

Radium-223 Treatment in mCRPC Patient with Polycythemia Vera
por: de Angelis, Cristina, et al.
Publicado: (2021)

Chemotherapy following radium‐223 dichloride treatment in ALSYMPCA
por: Sartor, Oliver, et al.
Publicado: (2016)

Radioligand therapy of metastatic prostate cancer using (177)Lu-PSMA-617 after radiation exposure to (223)Ra-dichloride
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2017)

Radium‐223 dichloride treatment in metastatic castration‐resistant prostate cancer in Finland: A real‐world evidence multicenter study
por: Hyväkkä, Anniina, et al.
Publicado: (2022)

Clinical aspects of mCRPC management in patients treated with radium-223
por: Rizzini, Elisa Lodi, et al.
Publicado: (2020)

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

Nanomicelles of Radium Dichloride [(223)Ra]RaCl(2) Co-Loaded with Radioactive Gold [(198)Au]Au Nanoparticles for Targeted Alpha–Beta Radionuclide Therapy of Osteosarcoma
por: Souza, Bárbara Nayane Rosário Fernandes, et al.
Publicado: (2022)

Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases
por: Yoshida, Keisuke, et al.
Publicado: (2016)

Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain
por: Tirado Mercier, Eva, et al.
Publicado: (2018)

Factors Influencing Outcome Post–Radium-223 Dichloride in Castrate Resistant Prostate Cancer: A Review of Some Real-World Challenges
por: Bhoil, Amit, et al.
Publicado: (2022)

The DASciS Software for BSI Calculation as a Valuable Prognostic Tool in mCRPC Treated with 223RaCl2: A Multicenter Italian Study
por: De Feo, Maria Silvia, et al.
Publicado: (2023)

Analysis of Unusual Adverse Effects After Radium-223 Dichloride  Administration
por: Frantellizzi, Viviana, et al.
Publicado: (2020)

Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT
por: Kairemo, Kalevi, et al.
Publicado: (2015)

Dynamic changes of bone metastasis predict bone‐predominant status to benefit from radium‐223 dichloride for patients with castration‐resistant prostate cancer
por: Hashimoto, Kohei, et al.
Publicado: (2020)

Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC)
por: Li, Yan, et al.
Publicado: (2022)

Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [(223)Ra]RaCl(2) therapy
por: Sraieb, Miriam, et al.
Publicado: (2020)

Health Economics and Radium-223 (Xofigo®) in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case History and a Systematic Review of the Literature
por: Norum, Jan, et al.
Publicado: (2016)

Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection
por: Den, Robert B., et al.
Publicado: (2019)

Radiopharmacokinetic modelling and radiation dose assessment of (223)Ra used for treatment of metastatic castration-resistant prostate cancer
por: Höllriegl, Vera, et al.
Publicado: (2021)

Laser isotope separation of (223)Ra
por: Suryanarayana, M. V.
Publicado: (2023)

Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223
por: Bauckneht, Matteo, et al.
Publicado: (2019)

Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases
por: Uemura, Hirotsugu, et al.
Publicado: (2019)

Sublethal exposure to alpha radiation ((223)Ra dichloride) enhances various carcinomas’ sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation
por: Malamas, Anthony S., et al.
Publicado: (2016)

Fine Structures in $^{14}C$ Emission of $^{223}Ra$ and $^{224}Ra$
por: Hourani, E, et al.
Publicado: (1991)

Targeted alpha therapy of mCRPC: Dosimetry estimate of (213)Bismuth-PSMA-617
por: Kratochwil, Clemens, et al.
Publicado: (2017)

Impact of Age at Diagnosis on Outcomes in Men with Castrate-Resistant Prostate Cancer (CRPC)
por: Humphreys, Michael R, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_va3uql0k6euv1ssr3q6hmva904